return equiti ttm
fourth-quart number expect guidanc
expect seem conserv
conclus stock thought
monday januari close report preliminari fourth-quart full-
year revenu million million respect result
ahead street expect million million
respect result line manag expect would come low
end million guidanc
manag expect revenu rang million
guidanc come slightli street expect call growth though
expect nonpublish expect probabl consist guidanc given abbott
market perform recent libr approv see note freestyl libr
medicar approv come earlier expect chang thesi
detail view guidanc conserv given assumpt bake detail
note believ manag purpos taken conserv rout given
expect move piec throughout year
updat model expect revenu million growth
despit guidanc call growth believ grow
world-wide sale come year view assumpt within guidanc
conserv addit libr marketplac medicar approv
add uncertainti regard patient addit price remain believ categori
abil multipl player win long-term potenti market remain larg
believ biggest determin stock next sever year
share trade time revenu target million rate
compani beat sale estim quarter manag attribut strong
domest patient add util well on-going intern strength abbott
commerci launch libr devic decemb manag believ launch
drive patient educ market
still manag assum neg impact guidanc
competit headwind could manifest form lower-than-expect
domest patient addit sensor price sensor util and/or attrit
year believ assumpt conserv although adjust estim
low end full-year revenu guidanc
make continu glucos monitor provid real-tim blood glucos measur trend
display vari period sound alarm patient blood-glucos level stray outsid predefin
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
tailwind year could push growth higher next sever quarter includ world-wide launch
calibr sensor anticip second half medicar expans despit libr
competit believ advantag popul particularli follow launch
calibr on-going intern expans manag recent secur increment germani payer
believ abbott pose biggest competit threat though expect compet
effect given enhanc product featur current lower price
outperform also look enter market stand-alon sensor view offer
compel enough real second competit threat
end ahead expect quarter full-year guidanc fourth-quart revenu
million full-year revenu million came million ahead street expect
million fourth quarter million full year result consist manag guidanc
call revenu come low end million million rang note manag suggest
fourth-quart commerci patient addit strong ever despit partial quarter impact
manag note hit goal global instal base patient impli ad roughli
patient platform net basi estim compani ad roughli patient gross basi
factor attrit
out-performance quarter driven domest commerci busi estim ad
patient estim gener revenu million ahead million target manag
note medicar contribut quarter fell short manag million expect
intern side believ intern came roughli line expect growth
year-over-year basi strong number patient addit like factor increas intern
awar on-going adopt germani
headwind guidanc guidanc call revenu growth rang million
believ street expect manag guidanc bake number assumpt
competit headwind domest patient addit sensor price sensor util attrit year
outlin manag assum neg impact guidanc factor discuss
potenti competit product threat competit dynam section howev note primari
chang model higher attrit rate chang sensor util
commerci patient add manag expect domest commerci patient grow conserv
model addit patient adult pediatr add
add commerci patient per quarter would add almost million domest target
manag believ world-wide instal base growth exceed overal revenu growth model reflect
assumpt instal base grow mainli fuel medicar intern patient add
price manag proactiv lower price without expand address market price
cut assum guidanc model assum price per sensor gradual decreas throughout cours
end end price hold stabl would add million
revenu estim also assum intern sensor price declin modestli
sensor util estim domest sensor util averag number day patient use sensor
increas day per sensor expect increas patient may buy fewer sensor due
new product trial model sensor util increas day full year
roughli day estim account expect util flat year-over-
year could equat million upsid domest estim
attrit guidanc also assum domest patient attrit drop rate step patient trial new product
market discuss patient mostli drop therapi two differ time frame immedi
patient buy system never use sometim first year patient trial time longer
want use lose reimburs coverag typic patient get past first year becom consist
user histor assum roughli annual domest attrit rate increas almost
annual expect assumpt could prove conserv note attrit rate
increas annual would add roughli million domest revenu target
tailwind guidanc
calibr launch manag express confid abil launch calibr world-wide
second half provid fda signific clinic data support product
confid go straight calibr system without mani issu would repres acceler
previou timelin one calibr approv calibr sometim follow new
libr calibr sensor would even play field metric potenti
acceler patient add current estim bake contribut new product launch
therefor revenu would upsid target
recal pre-pivot data achiev mean absolut rel differ mard one calibr
day mard calibr day believ fda may comfort
acceler timelin calibr label base improv accuraci approv libr
similar label despit lower accuraci without alert alarm
medicar manag still ramp direct-to-consum dtc market effort expect focu
patient popul first half year model medicar patient add equat
revenu million previous patient add equat million revenu given libr
medicar approv discuss howev expect increas dtc allow captur
mindshar patient add patient backlog compani still work fulfil
on-going european expans revenu growth expect exceed overal revenu growth
model intern revenu increment roughli million year-over-year believ could prove
conserv manag recent secur increment payer coverag germani bring total
coverag countri expect new cover live low-single-digit penetr
germani on-going reimburs buildout push intern estim higher throughout cours
partnership anima pump partnership longer contributor sale
outperform anoth pump partner launch new product omnipod dash
recent receiv medicar approv see note medicar part coverag open increment patient
popul includ estim detail sell sensor
new dash system two compani promot product conjunct expect
benefit partnership second half year
competit dynam multipl domest competit product launch potenti product approv
abbott year believ manag contempl
degre guidanc still experi market tend expand least two legitim
competit product market bring patient physician sidelin thu believ
abl benefit market growth come
believ abbott pose biggest competit threat though expect compet effect
given enhanc product featur current lower out-of-pocket price rel libr although libr run
price promot look enter market stand-alon sensor view
offer compel enough real second competit threat final competit product launch
expect late though patient percept reimburs challeng like face
expect real competit threat later given implant natur product need
extern transmitt mitig competit threat technolog leap calibr
expect
abbott libr view largest competit threat patient addit potenti year
someth extens discuss prior note product compet type market
compet market adult older anoth market medicar patient
believ still compet effect note benefit exclus cgm
product pediatr patient remain type market
expect commerci type diabet market split two differ camp cours
beyond high cost/sophist data cgm user low cost/low tech fgm user expect
patient choos libr want hassl alerts/alarm
still patient want true cgm devic alerts/alarm adopt date person reason
abbott establish big payer contract see price eventu lower howev
believ patient continu pay premium alerts/alarm abil share data dexcom
provid take dynam account essenti flat commerci patient add assumpt could
prove conserv thought view market shake cost analysi
provid note lower estim reflect freestyl libr impact chang may come
posit long term
regard medicar popul believ physician prescrib product patient
like use gain benefit weigh factor believ current form factor
allow win popul time alerts/alarm benefici patient popul
histori hypo-unawar thought popul provid note
freestyl libr medicar approv come earlier expect chang thesi
research indic abbott success type popul intern instal base
roughli mani endocrinologist posit devic type product could
posit dynam year commerci medicar popul
thought libr posit provid note patient diabet meet suggest strong interest
cgm libr view type product endocrinologist
return sensor manufactur capac like pose risk patient add
instal base still unduli concern competit threat given spotti histori
sensor space know product offer date
guardian connect mobil target second half fiscal sometim
end april launch stand-alon sensor platform product expect use medtron latest
guardian sensor last seven day improv accuraci rel older gener
sensor mard versu mard mard calibr abbott
mard still patient must take three four finger stick per day versu none cal libr
product abil let patient share glucos read like
believ product acceler market adopt cgm would expect dtc
market technolog stand-alon product market
believ increas effort decis make associ like make product
increment within exist pump-focus instal base three-to-four calibr stick
per day achiev decent accuraci guardian sensor also like impedi time
particularli abbott reduc calibr like requir calibr mid-
expand manufactur capac may modest neg effect portion user
base choos switch onto believ signific headwind major
new patient start year come multipl daili inject mdi
last quarterli call manag expect control second half roll-out
eversens implant cgm system assum panel meet discuss approv held earli howev
approv work payer get eversens exist coverag polici product
implant system would expect take compani navig reimburs landscap
implement new cgm code would expect real competit threat later
addit reimburs challeng expect devic face number patient challeng
devic implant surgic patient must receiv local anesthesia implant explant devic
hassl someth compani get patient comfort
model updat updat model accord manag initi revenu guidanc well
expect gross margin rang oper expens increas roughli
potenti coupl point spend nonintens initi
decreas full-year revenu estim million previous million
decreas net loss assumpt
